5660-34-4

Basic information

• Product Name: furo[3,4-b]quinoxaline-1,3-dione
• Synonyms: Furo(3,4-b)quinoxaline-1,3-dione; NSC 36328
• CAS NO: 5660-34-4
• Molecular Formula: C₁₀H₄N₂O₃
• Molecular Weight: 200.1504
• EINECS: 227-109-8
• Mol File: 5660-34-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 430.9°C at 760 mmHg
• Flash Point: 214.4°C
• Density: 1.625g/cm³
• Vapor Pressure: 1.25E-07mmHg at 25°C
• Refractive Index: 1.74
• CAS DataBase Reference: furo[3,4-b]quinoxaline-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: furo[3,4-b]quinoxaline-1,3-dione(5660-34-4)
• EPA Substance Registry System: furo[3,4-b]quinoxaline-1,3-dione(5660-34-4)

Safety Data

• Hazardous Substances Data: 5660-34-4(Hazardous Substances Data)

Upstream product

• 146651-75-4 tert–butyl (2–aminophenyl)carbamate 
• 54107-99-2 dimethyl quinoxaline-2,3-dicarboxylate 
• 95-54-5 1,2-diamino-benzene 
• 6924-99-8 Quinoxaline-2,3-dicarboxylic acid 

Downstream Products

• 54108-05-3 2-hydroxy-pyrrolo[3,4-b]quinoxaline-1,3-dione 
• 478060-30-9 3-(3-benzoyl-4,5,6,7-tetrahydro-benzo[b]thiophen-2-ylcarbamoyl)-quinoxaline-2-carboxylic acid 
• 320590-45-2 3-(2-carboxy-phenylcarbamoyl)-quinoxaline-2-carboxylic acid 
• 320590-48-5 2-[(quinoxaline-2-carbonyl)-amino]-benzoic acid methyl ester 
• 320590-46-3 3-(2-methoxycarbonyl-phenylcarbamoyl)-quinoxaline-2-carboxylic acid 

Relevant articles and documents

Synthesis, and pharmacological screening of novel sulfamoylphenylcarbamoylquinoxaline derivatives as anti-inflammatory, analgesic and antitumour agents

Treatment of quinoxaline-2,3-dicarboxylic acid anhydride with some sulfonamides gave 3-sulfamoylphenylcarbamoylquinoxaline-2-carboxylic acid derivatives. While fusing the anhydride with the same sulfonamides produced the corresponding 3-sulfamoylphenylcarbamoylquinoxalines. On refluxing 3-sulfamoylphenylcarbamoyl derivatives with acetic anhydride gave the pyrrolo[3,4-d]quinoxaline derivatives. The imide linkage in the latter compound was opened via its reaction with amines under fusion conditions and quinoxalin-2,3-diamides were obtained. The pharmacological evaluation for some of the synthesised compounds revealed that in anti-inflammatory activity in chronic models, 3-{[4-(N-pyrimidin-2-ylsulfamoyl)phenyl]carbamoyl}quinoxaline-2- carboxylic acid was equipotent to the reference drug, indomethacin as well as having nonulcerogenic effect. All tested compounds showed moderate analgesic activity compared to the reference drug. The antitumour activity for the tested compounds showed that 3-{[4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenyl] carbamoyl}quinoxaline-2-carboxylic acid, 4-(1,3-dioxo-1H-pyrrolo[3,4-b] quinoxalin-2(3H)-yl)-N-(pyrimidin-2-yl)-benzenesulfonamide and N-carbamimidoyl-4-(1,3-dioxo-1H-pyrrolo[3,4-b]quinoxalin-2(3H)-yl) benzenesulfonamide were the most effective against the liver carcinoma cell line showing IC50 values 0.5, 0.79 and 1.84 IC50 μg mL-1, respectively.